Crossover	crossover	O	O	O	O
comparison	comparison	O	O	O	O
of	of	O	O	O	O
efficacy	efficacy	O	O	O	O
and	and	O	O	O	O
preference	preference	O	O	O	O
for	for	O	O	O	O
rizatriptan	rizatriptan	CHEMICALS	O	OTHERS	I
10	10	O	O	O	O
mg	mg	O	O	OTHERS	I
versus	versus	O	O	O	O
ergotamine/caffeine	ergotamine/caffeine	O	O	O	O
in	in	O	O	O	O
migraine	migraine	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Rizatriptan	rizatriptan	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
a	a	O	O	O	O
selective	selective	O	O	O	O
5-HT(1B/1D	5-ht(1b/1d	O	O	O	O
)	)	O	O	O	O
receptor	receptor	O	O	O	O
agonist	agonist	O	O	O	O
with	with	O	O	O	O
rapid	rapid	O	O	O	O
oral	oral	O	O	O	O
absorption	absorption	O	O	O	O
and	and	O	O	O	O
early	early	O	O	O	O
onset	onset	O	O	O	O
of	of	O	O	O	O
action	action	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
acute	acute	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
migraine	migraine	O	DISEASE	OTHERS	I
.	.	O	O	O	O

This	this	O	O	O	O
randomized	randomized	O	O	O	O
double-	double-	O	O	O	O
blind	blind	O	O	OTHERS	I
crossover	crossover	O	O	O	O
outpatient	outpatient	O	O	O	O
study	study	O	O	O	O
assessed	assessed	O	O	O	O
the	the	O	O	O	O
preference	preference	O	O	O	O
for	for	O	O	O	O
1	1	O	O	O	O
rizatriptan	rizatriptan	CHEMICALS	O	OTHERS	I
10	10	O	O	O	O
mg	mg	O	O	OTHERS	I
tablet	tablet	O	O	O	O
to	to	O	O	O	O
2	2	O	O	O	O
ergotamine	ergotamine	CHEMICALS	O	OTHERS	I
1	1	O	O	O	O
mg/caffeine	mg/caffeine	O	O	O	O
100	100	O	O	O	O
mg	mg	O	O	OTHERS	I
tablets	tablets	O	O	O	O
in	in	O	O	O	O
439	439	O	O	O	O
patients	patients	O	O	O	O
treating	treating	O	O	O	O
a	a	O	O	O	O
single	single	O	O	O	O
migraine	migraine	O	DISEASE	OTHERS	I
attack	attack	O	O	O	O
with	with	O	O	O	O
each	each	O	O	O	O
therapy	therapy	O	O	O	O
.	.	O	O	O	O

Of	of	O	O	O	O
patients	patients	O	O	O	O
expressing	expressing	O	O	O	O
a	a	O	O	O	O
preference	preference	O	O	O	O
(	(	O	O	O	O
89.1	89.1	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
more	more	O	O	O	O
than	than	O	O	O	O
twice	twice	O	O	O	O
as	as	O	O	O	O
many	many	O	O	O	O
preferred	preferred	O	O	O	O
rizatriptan	rizatriptan	CHEMICALS	O	OTHERS	I
to	to	O	O	O	O
ergotamine/caffeine	ergotamine/caffeine	O	O	O	O
(	(	O	O	O	O
69.9	69.9	O	O	O	O
vs.	vs.	O	O	O	O
30.1	30.1	O	O	O	O
%	%	O	O	O	O
,	,	O	O	O	O
p	p	O	O	OTHERS	I
<	<	O	O	O	O
or	or	O	O	O	O
=	=	O	O	O	O
0.001	0.001	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Faster	faster	O	O	O	O
relief	relief	O	O	O	O
of	of	O	O	O	O
headache	headache	O	DISEASE	OTHERS	I
was	was	O	O	O	O
the	the	O	O	O	O
most	most	O	O	O	O
important	important	O	O	O	O
reason	reason	O	O	O	O
for	for	O	O	O	O
preference	preference	O	O	O	O
,	,	O	O	O	O
cited	cited	O	O	O	O
by	by	O	O	O	O
67.3	67.3	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
preferring	preferring	O	O	O	O
rizatriptan	rizatriptan	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
54.2	54.2	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
preferred	preferred	O	O	O	O
ergotamine/caffeine	ergotamine/caffeine	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
co-primary	co-primary	O	O	O	O
endpoint	endpoint	O	O	O	O
of	of	O	O	O	O
being	being	O	O	O	O
pain	pain	O	DISEASE	OTHERS	I
free	free	O	O	O	O
at	at	O	O	O	O
2	2	O	O	O	O
h	h	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
also	also	O	O	O	O
in	in	O	O	O	O
favor	favor	O	O	O	O
of	of	O	O	O	O
rizatriptan	rizatriptan	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Forty-nine	forty-nine	O	O	O	O
percent	percent	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
pain	pain	O	DISEASE	OTHERS	I
free	free	O	O	O	O
2	2	O	O	O	O
h	h	CHEMICALS	O	OTHERS	I
after	after	O	O	O	O
rizatriptan	rizatriptan	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
compared	compared	O	O	O	O
with	with	O	O	O	O
24.3	24.3	O	O	O	O
%	%	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
ergotamine/caffeine	ergotamine/caffeine	O	O	O	O
(	(	O	O	O	O
p	p	O	O	OTHERS	I
<	<	O	O	O	O
or	or	O	O	O	O
=	=	O	O	O	O
0.001	0.001	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
rizatriptan	rizatriptan	CHEMICALS	O	OTHERS	I
being	being	O	O	O	O
superior	superior	O	O	O	O
within	within	O	O	O	O
1	1	O	O	O	O
h	h	CHEMICALS	O	OTHERS	I
of	of	O	O	O	O
treatment	treatment	O	O	O	O
.	.	O	O	O	O

Headache	headache	O	DISEASE	OTHERS	I
relief	relief	O	O	O	O
at	at	O	O	O	O
2	2	O	O	O	O
h	h	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
75.9	75.9	O	O	O	O
%	%	O	O	O	O
for	for	O	O	O	O
rizatriptan	rizatriptan	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
47.3	47.3	O	O	O	O
%	%	O	O	O	O
for	for	O	O	O	O
ergotamine/caffeine	ergotamine/caffeine	O	O	O	O
(	(	O	O	O	O
p	p	O	O	OTHERS	I
<	<	O	O	O	O
or	or	O	O	O	O
=	=	O	O	O	O
0.001	0.001	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
rizatriptan	rizatriptan	CHEMICALS	O	OTHERS	I
being	being	O	O	O	O
superior	superior	O	O	O	O
to	to	O	O	O	O
ergotamine/caffeine	ergotamine/caffeine	O	O	O	O
within	within	O	O	O	O
30	30	O	O	O	O
min	min	O	O	O	O
of	of	O	O	O	O
dosing	dosing	O	O	O	O
.	.	O	O	O	O

Almost	almost	O	O	O	O
36	36	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
taking	taking	O	O	O	O
rizatriptan	rizatriptan	CHEMICALS	O	OTHERS	I
were	were	O	O	O	O
pain	pain	O	DISEASE	OTHERS	I
free	free	O	O	O	O
at	at	O	O	O	O
2	2	O	O	O	O
h	h	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
had	had	O	O	O	O
no	no	O	O	O	O
recurrence	recurrence	O	O	O	O
or	or	O	O	O	O
need	need	O	O	O	O
for	for	O	O	O	O
additional	additional	O	O	O	O
medication	medication	O	O	O	O
within	within	O	O	O	O
24	24	O	O	O	O
h	h	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
compared	compared	O	O	O	O
to	to	O	O	O	O
20	20	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
on	on	O	O	O	O
ergotamine/caffeine	ergotamine/caffeine	O	O	O	O
(	(	O	O	O	O
p	p	O	O	OTHERS	I
<	<	O	O	O	O
or	or	O	O	O	O
=	=	O	O	O	O
0.001	0.001	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Rizatriptan	rizatriptan	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
also	also	O	O	O	O
superior	superior	O	O	O	O
to	to	O	O	O	O
ergotamine/caffeine	ergotamine/caffeine	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
proportions	proportions	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
no	no	O	O	O	O
nausea	nausea	O	DISEASE	OTHERS	I
,	,	O	O	OTHERS	I
vomiting	vomiting	O	DISEASE	OTHERS	I
,	,	O	O	O	O
phonophobia	phonophobia	O	O	OTHERS	I
or	or	O	O	O	O
photophobia	photophobia	O	O	OTHERS	I
and	and	O	O	O	O
for	for	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
normal	normal	O	O	O	O
function	function	O	O	O	O
2	2	O	O	O	O
h	h	CHEMICALS	O	OTHERS	I
after	after	O	O	O	O
drug	drug	O	O	O	O
intake	intake	O	O	O	O
(	(	O	O	O	O
p	p	O	O	OTHERS	I
<	<	O	O	O	O
or	or	O	O	O	O
=	=	O	O	O	O
0.001	0.001	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

More	more	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
(	(	O	O	O	O
completely	completely	O	O	O	O
,	,	O	O	O	O
very	very	O	O	O	O
or	or	O	O	O	O
somewhat	somewhat	O	O	O	O
)	)	O	O	O	O
satisfied	satisfied	O	O	O	O
2	2	O	O	O	O
h	h	CHEMICALS	O	OTHERS	I
after	after	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
rizatriptan	rizatriptan	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
69.8	69.8	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
than	than	O	O	O	O
at	at	O	O	O	O
2	2	O	O	O	O
h	h	CHEMICALS	O	OTHERS	I
after	after	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
ergotamine/caffeine	ergotamine/caffeine	O	O	O	O
(	(	O	O	O	O
38.6	38.6	O	O	O	O
%	%	O	O	O	O
,	,	O	O	O	O
p	p	O	O	OTHERS	I
<	<	O	O	O	O
or	or	O	O	O	O
=	=	O	O	O	O
0.001	0.001	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Recurrence	recurrence	O	O	O	O
rates	rates	O	O	O	O
were	were	O	O	O	O
31.4	31.4	O	O	O	O
%	%	O	O	O	O
with	with	O	O	O	O
rizatriptan	rizatriptan	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
15.3	15.3	O	O	O	O
%	%	O	O	O	O
with	with	O	O	O	O
ergotamine/caffeine	ergotamine/caffeine	O	O	O	O
.	.	O	O	O	O

Both	both	O	O	O	O
active	active	O	O	O	O
treatments	treatments	O	O	O	O
were	were	O	O	O	O
well	well	O	O	O	O
tolerated	tolerated	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
most	most	O	O	O	O
common	common	O	O	O	O
adverse	adverse	O	O	O	O
events	events	O	O	O	O
(	(	O	O	O	O
incidence	incidence	O	O	O	O
>	>	O	O	O	O
or	or	O	O	O	O
=	=	O	O	O	O
5	5	O	O	O	O
%	%	O	O	O	O
in	in	O	O	O	O
one	one	O	O	O	O
group	group	O	O	O	O
)	)	O	O	O	O
after	after	O	O	O	O
rizatriptan	rizatriptan	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
ergotamine/caffeine	ergotamine/caffeine	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
,	,	O	O	O	O
were	were	O	O	O	O
dizziness	dizziness	O	DISEASE	OTHERS	I
(	(	O	O	O	O
6.7	6.7	O	O	O	O
and	and	O	O	O	O
5.3	5.3	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
nausea	nausea	O	DISEASE	OTHERS	I
(	(	O	O	O	O
4.2	4.2	O	O	O	O
and	and	O	O	O	O
8.5	8.5	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
somnolence	somnolence	O	DISEASE	OTHERS	I
(	(	O	O	O	O
5.5	5.5	O	O	O	O
and	and	O	O	O	O
2.3	2.3	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

